GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Average Recommendation of “Buy” from Brokerages

GeoVax Labs, Inc. (NASDAQ:GOVX) has received an average recommendation of “Buy” from the seven analysts that are currently covering the company, MarketBeat reports. Five investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $14.20.

A number of brokerages have recently weighed in on GOVX. Alliance Global Partners started coverage on GeoVax Labs in a report on Monday, November 11th. They issued a “buy” rating and a $15.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of GeoVax Labs in a research note on Friday, November 15th. Finally, D. Boral Capital restated a “buy” rating and issued a $18.00 price target on shares of GeoVax Labs in a research report on Wednesday, December 18th.

GeoVax Labs Price Performance

Shares of GOVX stock opened at $2.64 on Tuesday. The firm has a fifty day moving average of $2.42 and a two-hundred day moving average of $2.82. GeoVax Labs has a 1-year low of $1.09 and a 1-year high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.38. The firm had revenue of $2.79 million during the quarter, compared to analyst estimates of $1.84 million. During the same quarter last year, the business posted ($4.80) earnings per share. On average, research analysts forecast that GeoVax Labs will post -4.49 EPS for the current fiscal year.

Institutional Trading of GeoVax Labs

An institutional investor recently bought a new position in GeoVax Labs stock. Virtu Financial LLC purchased a new stake in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned about 0.43% of GeoVax Labs at the end of the most recent quarter. Hedge funds and other institutional investors own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.